Tabetha Fleszar
Family · Paragould, ARNPI 1649946120
Payments from drug & device makers
Across 99 payments — averaging $23.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$736
- Myriad Genetic Laboratories, Inc.$195
- Astellas Pharma US Inc$177
- Dendreon Pharmaceuticals LLC$166
- Myovant Sciences Inc.$145
- Endo Pharmaceuticals Inc.$123
- plus $824 from 20 others
What the payments were for
- Travel & lodging$1717%
- Food & beverage$2,07888%
- Education$1165%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 19 | $736 |
| Myriad Genetic Laboratories, Inc. | 7 | $195 |
| Astellas Pharma US Inc | 8 | $177 |
| Dendreon Pharmaceuticals LLC | 10 | $166 |
| Myovant Sciences Inc. | 2 | $145 |
| Endo Pharmaceuticals Inc. | 8 | $123 |
| AbbVie | 6 | $109 |
| Johnson & Johnson | 6 | $96 |
| AstraZeneca | 1 | $85 |
| Tolmar Pharmaceuticals, Inc. | 4 | $70 |
| Procept Biorobotics Corporation | 3 | $65 |
| Sumitomo Pharma America, Inc. | 3 | $45 |
| Axonics, Inc. | 3 | $44 |
| Urovant Sciences Inc | 3 | $43 |
| Bayer | 2 | $39 |
| Tolmar, Inc. | 2 | $35 |
| Merck | 2 | $31 |
| Boston Scientific | 2 | $30 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $22 |
| Antares Pharma, Inc. | 1 | $22 |
| Urogen Pharma, Inc. | 1 | $17 |
| Pfizer | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| Coloplast | 1 | $13 |
| Halozyme Inc | 1 | $13 |
| 180 Medical, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,365 in reported general payments places this provider in the 80th percentile of 2,103 family providers in Arkansas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 11 | $160,111 |
| MyrbetriqMirabegron | 62 | $33,621 |
| GemtesaVibegron | 29 | $21,515 |
| Tamsulosin Hcl | 64 | $923 |
| Solifenacin Succinate | 26 | $717 |
| Cephalexin | 20 | $223 |
| Finasteride | 12 | $157 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $177 | $193,73273 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $45 | $21,51529 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,103 family providers in Arkansas.
Other family in Paragould
- Cecil MasseyParagould$13K
- Teresa GonzalezParagould$12K
- Latoya CowardParagould$11K
- Leah CarringtonRogers$1.6M
- Nina CopelandFort Smith$207K
- Stefanie BrackinJonesboro$51K
- Amanda DavisFort Smith$46K
- Allison HittManila$40K
- Kimberly GatesNorth Little Rock$31K
- Meghan MallettConway$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.